Century Therapeutics, Inc.

NASDAQ:IPSC

0.543 (USD) • At close July 1, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 109.1644.1730.7910.7710.8550.2680.1480.0991.720.5212.2241.3961.05800000000
Cost of Revenue 000003.5521.7872.4092.173.3832.7741.66821.1961.8851.0440.9350.9480000
Gross Profit 109.1644.1730.7910.7710.855-3.284-1.639-2.31-0.45-2.862-0.55-0.272-20.138-1.885-1.044-0.935-0.9480000
Gross Profit Ratio 11111-12.254-11.074-23.333-0.262-5.493-0.247-0.195-19.03400000000
Reseach & Development Expenses 26.5829.37527.22827.2223.42122.29622.78822.72724.89925.58525.89824.49431.19621.79619.54518.93315.37412.44210.8128.4847.943
General & Administrative Expenses 8.4087.7558.3528.3068.7438.5898.9868.2298.9028.2428.0648.2537.2986.1776.2824.0882.6882.8162.3192.312.05
Selling & Marketing Expenses 000000000000000000000
SG&A 8.4087.7558.3528.3068.7438.5898.9868.2298.9028.2428.0648.2537.2986.1776.2824.0882.6882.8162.3192.312.05
Other Expenses 04.32700013.1450.012-0.186-0.1942.0691.3870100000.0280000.32
Operating Expenses 34.98841.45735.5835.52632.16444.0331.77430.95633.80133.82733.96232.74738.49427.97325.82723.02118.06215.25813.13110.7949.993
Operating Income 74.176-37.284-34.789-34.755-31.309-43.762-35.626-35.077-32.081-33.306-31.738-31.351-37.436-27.973-25.827-23.021-18.062-15.258-13.131-15.516-9.993
Operating Income Ratio 0.679-8.935-43.981-45.078-36.619-163.291-240.716-354.313-18.652-63.927-14.271-22.458-35.38400000000
Total Other Income Expenses Net 2.3842.9873.5553.573.2483.4953.4982.7362.0251.6561.0140.381-0.061-0.178-0.182-0.252-0.286-0.2730.0610.2150.32
Income Before Tax 76.56-34.297-31.234-31.185-28.061-40.267-32.128-32.341-30.056-31.65-30.724-30.97-37.497-28.151-26.009-23.273-18.348-15.531-13.07-15.301-9.673
Income Before Tax Ratio 0.701-8.219-39.487-40.447-32.82-150.25-217.081-326.677-17.474-60.749-13.815-22.185-35.44100000000
Income Tax Expense 01.776-0.0080.0220.001-0.8690.5920.951.2080.0320.0250.0180.0160.0430.063-0.010.3421.040.10600.32
Net Income 76.56-36.073-31.226-31.207-28.062-39.398-32.72-33.291-31.264-31.682-30.749-30.988-37.513-28.194-26.009-23.273-18.348-15.531-13.07-15.301-9.673
Net Income Ratio 0.701-8.644-39.477-40.476-32.821-147.007-221.081-336.273-18.177-60.81-13.826-22.198-35.45700000000
EPS 0.89-0.46-0.37-0.38-0.45-0.66-0.55-0.56-0.53-0.54-0.53-0.54-0.66-0.52-0.48-0.43-0.33-0.37-0.31-0.37-0.23
EPS Diluted 0.89-0.46-0.37-0.38-0.45-0.66-0.55-0.56-0.53-0.54-0.53-0.54-0.66-0.52-0.48-0.43-0.33-0.37-0.31-0.37-0.23
EBITDA 77.397-30.979-27.936-27.723-28.083-36.715-30.341-29.796-27.482-27.854-27.577-28.972-37.183-26.922-24.643-22.086-17.316-14.685-12.601-15.019-9.414
EBITDA Ratio 0.709-7.424-35.317-35.957-32.846-136.996-205.007-300.97-15.978-53.463-12.4-20.754-35.14500000000